Ing S. Tiong

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications

Clonal ancestry in AML: insights from founding genetic events.

Clonal ancestry in AML: insights from founding genetic events.

Journal: Leukemia & lymphoma
Published: May 25, 2026

A quantitative definition of the clinical manifestations of GATA2 deficiency in adults.

A quantitative definition of the clinical manifestations of GATA2 deficiency in adults.

Journal: Blood
Published: May 18, 2026

Neutropenia Duration During AZA-VEN Induction for AML Is Bimodal and Correlates With Infection Risk.

Neutropenia Duration During AZA-VEN Induction for AML Is Bimodal and Correlates With Infection Risk.

Journal: Blood advances
Published: May 05, 2026

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

Journal: Blood
Published: February 04, 2026

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

Journal: Blood
Published: February 04, 2026

The telomeric puzzle in TP53-mutant myeloid neoplasms.

The telomeric puzzle in TP53-mutant myeloid neoplasms.

Journal: Blood
Published: January 08, 2026

Activating somatic EPOR mutation in primary erythrocytosis.

Activating somatic EPOR mutation in primary erythrocytosis.

Journal: Pathology
Published: December 22, 2025

Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.

Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.

Journal: Leukemia
Published: October 09, 2025

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

Journal: Blood
Published: September 16, 2025

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.

Journal: Blood
Published: September 16, 2025

Myeloid/lymphoid neoplasms with eosinophilia and ZMYM2::FLT3 fusion: clinical, pathological and molecular clues to a cryptic diagnosis.

Myeloid/lymphoid neoplasms with eosinophilia and ZMYM2::FLT3 fusion: clinical, pathological and molecular clues to a cryptic diagnosis.

Journal: Pathology
Published: September 03, 2025

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Journal: Blood advances
Published: May 06, 2025
Showing 1-12 of 76

Last Updated: 09/26/2026